Vasculitis & polymyalgia rheumatica
Impact of antineutrophil cytoplasmic antibodies (ANCA) specificity on risk of cardiovascular events and death in ANCA-associated vasculitis
Main finding · MACE incidence rateResult — go to the resultHazard ratio 1.62 95% CI 0.98–2.66Authors' conclusion
Patients with anti-MPO ANCA appear to be at a higher risk of a composite MACE-all-cause mortality outcome than patients with anti-PR3 ANCA.
Study context
- Population
- Patients with ANCA-associated vasculitis (AAV), ANCA-associated vasculitis Toulouse cohort78 major adverse cardiovascular events (MACE) during follow-up
- Participants
- 402 patients
- Exposure
- Anti-MPO ANCA vs anti-PR3 ANCA
- ANCA+anti-PR3+n = 166reference
- ANCA+antimyeloperoxidase (anti-MPO)+n = 236
- Outcome
- MACE (MI and/or stroke and/or all-cause death)
Methodological detailsCox regression adjusted for traditional cardiovascular risk factors, age and sex
- Cox regression adjusted for traditional cardiovascular risk factors, age and sex
Main finding
MACE incidence rate
Hazard ratio
1.62
95% CI 0.98–2.66
P = 0.06
By group
ANCA+anti-MPO+vs ANCA+anti-PR3+
HR 1.62 (95% CI 0.98–2.66); P = 0.06
As reported in the abstract
Observational data: associations, not effects.
Further findings
Stroke
| HR (95% CI) | P value | ||
|---|---|---|---|
| ANCA+anti-PR3+Cox regression, adjusted | 0.61 (0.37–0.99) | P = 0.049 | |
| 0.20.5125Hazard ratio (log scale) |
Time from AAV diagnosis to MACE
- Significantly shorter in ANCA+anti-MPO+
Myocardial infarction (MI)
- No association with anti-PR3 ANCA
Event components
- MIs
- 15
- Strokes
- 12
- Deaths
- 62
Original publication
Impact of ANCA specificity on risk of cardiovascular events and death in ANCA-associated vasculitis. RMD Open. Published 22 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →